ZSWIM7

Summary

ZSWIM7 (zinc finger SWIM-type containing 7, HGNC:26993) is a protein-coding gene on chromosome 17p12, encoding Zinc finger SWIM domain-containing protein 7 (Q19AV6). Involved in early stages of the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents.

Predicted to enable zinc ion binding activity. Involved in double-strand break repair via homologous recombination and protein stabilization. Part of Shu complex. Implicated in ovarian dysgenesis 10 and spermatogenic failure 71.

Source: NCBI Gene 125150 — RefSeq curated summary.

At a glance

• Gene–disease (curated): ovarian dysgenesis 10 (Strong, GenCC) — +2 more curated relationships
• GWAS associations: 1
• Clinical variants (ClinVar): 35 total — 2 pathogenic, 2 likely-pathogenic
• Phenotypes (HPO): 39
• MANE Select transcript: NM_001042697

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26993
Approved symbol	ZSWIM7
Name	zinc finger SWIM-type containing 7
Location	17p12
Locus type	gene with protein product
Status	Approved
Aliases	SWS1
Ensembl gene	ENSG00000214941
Ensembl biotype	protein_coding
OMIM	614535
Entrez	125150

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 10 nonsense_mediated_decay, 9 protein_coding, 5 protein_coding_CDS_not_defined

ENST00000399277, ENST00000399280, ENST00000460252, ENST00000460315, ENST00000472495, ENST00000474716, ENST00000475498, ENST00000476496, ENST00000486655, ENST00000486706, ENST00000490395, ENST00000491631, ENST00000495825, ENST00000497434, ENST00000497719, ENST00000579955, ENST00000584519, ENST00000585208, ENST00000888428, ENST00000888429, ENST00000888430, ENST00000922667, ENST00000946547, ENST00000946548

RefSeq mRNA: 2 — MANE Select: NM_001042697 NM_001042697, NM_001042698

CCDS: CCDS42266

Canonical transcript exons

ENST00000399277 — 5 exons

Exon	Start	End
ENSE00001537338	15999519	15999704
ENSE00003508283	15976560	15978163
ENSE00003549628	15981040	15981144
ENSE00003618108	15987266	15987368
ENSE00003627730	15993757	15993778

Expression profiles

Bgee: expression breadth ubiquitous, 250 present calls, max score 95.86.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 24.6477 / max 250.2296, expressed in 1815 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
164709	12.0710	1790
164710	11.3898	1782
164708	1.1868	742

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tendon of biceps brachii	UBERON:0008188	95.86	gold quality
right adrenal gland cortex	UBERON:0035827	94.14	gold quality
left adrenal gland	UBERON:0001234	93.74	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	93.66	gold quality
hindlimb stylopod muscle	UBERON:0004252	93.62	gold quality
left adrenal gland cortex	UBERON:0035825	93.62	gold quality
right adrenal gland	UBERON:0001233	93.57	gold quality
gastrocnemius	UBERON:0001388	93.49	gold quality
muscle of leg	UBERON:0001383	93.30	gold quality
monocyte	CL:0000576	92.96	gold quality
leukocyte	CL:0000738	92.85	gold quality
metanephros cortex	UBERON:0010533	92.73	gold quality
oocyte	CL:0000023	92.71	gold quality
prefrontal cortex	UBERON:0000451	92.69	gold quality
islet of Langerhans	UBERON:0000006	92.66	gold quality
adenohypophysis	UBERON:0002196	92.60	gold quality
adrenal cortex	UBERON:0001235	92.59	gold quality
anterior cingulate cortex	UBERON:0009835	92.57	gold quality
tibialis anterior	UBERON:0001385	92.56	silver quality
hypothalamus	UBERON:0001898	92.53	gold quality
left ovary	UBERON:0002119	92.53	gold quality
body of pancreas	UBERON:0001150	92.44	gold quality
adrenal gland	UBERON:0002369	92.35	gold quality
right ovary	UBERON:0002118	92.22	gold quality
left ventricle myocardium	UBERON:0006566	91.95	gold quality
spinal cord	UBERON:0002240	91.92	gold quality
amygdala	UBERON:0001876	91.91	gold quality
apex of heart	UBERON:0002098	91.89	gold quality
pituitary gland	UBERON:0000007	91.80	gold quality
granulocyte	CL:0000094	91.79	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

43 targeting ZSWIM7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-4320	99.75	65.80	793
HSA-MIR-2681-5P	99.75	67.64	1655
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-7161-5P	99.68	68.92	1592
HSA-MIR-548U	99.65	67.78	1463
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-24-3P	99.59	69.97	1934
HSA-MIR-3923	99.52	69.21	446
HSA-MIR-4325	99.49	72.20	1342
HSA-MIR-6740-3P	99.48	68.49	1392
HSA-MIR-4728-3P	99.47	68.94	981
HSA-MIR-578	99.46	68.36	1787
HSA-MIR-3182	99.40	68.15	2454
HSA-MIR-324-3P	99.26	66.31	1034
HSA-MIR-4727-5P	99.23	67.55	1154
HSA-MIR-877-3P	99.09	68.10	1637
HSA-MIR-371A-5P	99.08	66.51	1914
HSA-MIR-140-3P	99.04	67.69	1324
HSA-MIR-6814-5P	99.03	66.68	1273
HSA-MIR-452-3P	99.01	66.25	1241
HSA-MIR-367-5P	98.84	67.18	902

Literature-anchored findings (GeneRIF, showing 5)

• A recurrent ZSWIM7 mutation causes male infertility resulting from decreased meiotic recombination. (PMID:33713115)
• ZSWIM7 Is Associated With Human Female Meiosis and Familial Primary Ovarian Insufficiency. (PMID:34402903)
• Pathogenic Variants in ZSWIM7 Cause Primary Ovarian Insufficiency. (PMID:35218660)
• A novel homozygous variant in homologous recombination repair gene ZSWIM7 causes azoospermia in males and primary ovarian insufficiency in females. (PMID:36202298)
• The human Shu complex promotes RAD51 activity by modulating RPA dynamics on ssDNA. (PMID:39169038)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	zswim7	ENSDARG00000067608
mus_musculus	Zswim7	ENSMUSG00000014243
rattus_norvegicus	Zswim7	ENSRNOG00000002970

Protein

Protein identifiers

Zinc finger SWIM domain-containing protein 7 — Q19AV6 (reviewed: Q19AV6)

Alternative names: SWIM domain-containing and Srs2-interacting protein 1 homolog, SWIM-type zinc finger domain-containing protein 7

All UniProt accessions (7): J3KRY0, J3QL97, J3QLK2, J3QRT4, J3QS07, J3QS31, Q19AV6

UniProt curated annotations — full annotation on UniProt →

Function. Involved in early stages of the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. Required for meiotic progression, hence for fertility.

Subunit / interactions. Interacts with RAD51D and XRCC3; involved in homologous recombination repair. Interacts with SWSAP1; they form a functional complex involved in homologous recombination repair and stabilize each other.

Subcellular location. Nucleus.

Tissue specificity. Expressed in ovary and testis.

Disease relevance. Ovarian dysgenesis 10 (ODG10) [MIM:619834] An autosomal recessive form of ovarian dysgenesis, a disorder characterized by lack of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hypogonadism as a result of streak gonads. The disease is caused by variants affecting the gene represented in this entry. Spermatogenic failure 71 (SPGF71) [MIM:619831] An autosomal recessive male infertility disorder characterized by non-obstructive azoospermia. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the SWS1 family.

RefSeq proteins (2): NP_001036162, NP_001036163 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007527	Znf_SWIM	Domain

Pfam: PF04434

UniProt features (3 total): chain 1, zinc finger region 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q19AV6-F1	92.13	0.87

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 148 (showing top): chr17p12, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_PROTEIN_STABILIZATION, GOBP_DNA_DAMAGE_RESPONSE, GOBP_REGULATION_OF_PROTEIN_STABILITY, GOBP_RECOMBINATIONAL_REPAIR, GOBP_DNA_METABOLIC_PROCESS, GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_UP, GOBP_DNA_REPAIR, THUM_SYSTOLIC_HEART_FAILURE_DN, GOBP_DNA_RECOMBINATION, YOSHIMURA_MAPK8_TARGETS_UP, PANGAS_TUMOR_SUPPRESSION_BY_SMAD1_AND_SMAD5_DN, TURASHVILI_BREAST_NORMAL_DUCTAL_VS_LOBULAR_UP, PILON_KLF1_TARGETS_UP

GO Biological Process (5): double-strand break repair via homologous recombination (GO:0000724), protein stabilization (GO:0050821), DNA repair (GO:0006281), DNA recombination (GO:0006310), DNA damage response (GO:0006974)

GO Molecular Function (3): zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleus (GO:0005634), Shu complex (GO:0097196)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA metabolic process	2
recombinational repair	1
double-strand break repair	1
regulation of protein stability	1
DNA damage response	1
cellular response to stress	1
transition metal ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
protein-containing complex	1

Protein interactions and networks

STRING

486 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZSWIM7	SWSAP1	Q6NVH7	749
ZSWIM7	TTC19	Q6DKK2	530
ZSWIM7	ELOF1	P60002	528
ZSWIM7	MAGEE2	Q8TD90	497
ZSWIM7	MRPL51	Q4U2R6	493
ZSWIM7	MICOS10	Q5TGZ0	464
ZSWIM7	ZNF827	Q17R98	446
ZSWIM7	TERB1	Q8NA31	438
ZSWIM7	FBXO38	Q6PIJ6	427
ZSWIM7	LRRC37A2	A6NM11	419
ZSWIM7	MRPL48	Q96GC5	416
ZSWIM7	TIMM8B	Q9Y5J9	409
ZSWIM7	TAPT1	Q6NXT6	393
ZSWIM7	SAP30BP	Q9UHR5	383
ZSWIM7	KANSL1	Q7Z3B3	369

IntAct

35 interactions, top by confidence:

A	B	Type	Score
ZSWIM7	SWSAP1	psi-mi:“MI:0915”(physical association)	0.900
SWSAP1	ZSWIM7	psi-mi:“MI:0915”(physical association)	0.900
SWSAP1	SPIDR	psi-mi:“MI:0915”(physical association)	0.720
ZSWIM7	SPIDR	psi-mi:“MI:0915”(physical association)	0.660
SPIDR	ZSWIM7	psi-mi:“MI:0915”(physical association)	0.660
UQCRB	ZSWIM7	psi-mi:“MI:0915”(physical association)	0.560
SWSAP1	GAPDHS	psi-mi:“MI:0914”(association)	0.530
PLA2G10	CHEK1	psi-mi:“MI:0914”(association)	0.530
ZSWIM7	PDS5B	psi-mi:“MI:0915”(physical association)	0.470
ZSWIM7	RAD51D	psi-mi:“MI:0915”(physical association)	0.400
ZSWIM7	XRCC3	psi-mi:“MI:0915”(physical association)	0.400
ZSWIM7	RAC3	psi-mi:“MI:0914”(association)	0.350

BioGRID (27): SWSAP1 (Two-hybrid), ZSWIM7 (Affinity Capture-MS), ZSWIM7 (Affinity Capture-MS), ZSWIM7 (Two-hybrid), SWSAP1 (Two-hybrid), ZSWIM7 (Affinity Capture-RNA), ZSWIM7 (Two-hybrid), ZSWIM7 (Two-hybrid), ZSWIM7 (Affinity Capture-MS), RAC3 (Affinity Capture-MS), HSPA1A (Affinity Capture-MS), ZSWIM7 (Affinity Capture-MS), SPIDR (Affinity Capture-MS), ZSWIM7 (Affinity Capture-MS), ZSWIM7 (Affinity Capture-MS)

ESM2 similar proteins: A2A825, A4FVI0, E1C6Q1, E9PTA2, O15315, O35719, O43502, O54804, O95059, O95803, P22339, P47802, Q01134, Q19AV6, Q33DR3, Q3U129, Q3U2J5, Q3UFY7, Q3ZBL5, Q4R7M4, Q5BIM1, Q5PPH0, Q5R812, Q5RB79, Q5VYX0, Q5ZJB7, Q6DC64, Q6GV29, Q6P4H8, Q7Z624, Q80ZQ9, Q86YH6, Q8CIW5, Q8NBA8, Q8R1C6, Q8R2J9, Q91YD4, Q924H5, Q96IK5, Q96RR1

Diamond homologs: A4FVI0, Q19AV6, Q55FI7, Q9CWQ2

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
ZSWIM7	“form complex”	“SHU complex”	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

35 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	2
Uncertain significance	19
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
1676297	NM_001042697.2(ZSWIM7):c.201+1G>T	Pathogenic
1676582	NM_001042697.2(ZSWIM7):c.173C>G (p.Ser58Ter)	Pathogenic
1013608	NM_001042697.2(ZSWIM7):c.231_232del (p.Cys78fs)	Likely pathogenic
1699948	NM_001042697.2(ZSWIM7):c.176C>T (p.Ser59Leu)	Likely pathogenic

SpliceAI

1221 predictions. Top by Δscore:

Variant	Effect	Δscore
17:15987368:CCTGT:C	acceptor_loss	1.0000
17:15987369:C:CG	acceptor_loss	1.0000
17:15987370:T:A	acceptor_loss	1.0000
17:15993779:C:CC	acceptor_gain	1.0000
17:15999517:A:AC	donor_gain	1.0000
17:15999518:C:CC	donor_gain	1.0000
17:15999520:T:TA	donor_gain	1.0000
17:15999530:T:A	donor_gain	1.0000
17:15978164:C:CC	acceptor_gain	0.9900
17:15980996:TCTC:T	donor_gain	0.9900
17:15981009:C:CT	donor_gain	0.9900
17:15981010:T:TT	donor_gain	0.9900
17:15987260:TTCTA:T	donor_loss	0.9900
17:15987261:TCTA:T	donor_loss	0.9900
17:15987262:CTAC:C	donor_loss	0.9900
17:15987263:TAC:T	donor_loss	0.9900
17:15987264:A:AG	donor_loss	0.9900
17:15987265:C:CT	donor_loss	0.9900
17:15987266:C:G	donor_loss	0.9900
17:15987281:T:TA	donor_gain	0.9900
17:15987369:C:CC	acceptor_gain	0.9900
17:15993755:A:AC	donor_gain	0.9900
17:15993756:C:CC	donor_gain	0.9900
17:15999518:CTT:C	donor_gain	0.9900
17:15999518:CTTCG:C	donor_gain	0.9900
17:15978160:TGCA:T	acceptor_gain	0.9800
17:15978162:CA:C	acceptor_gain	0.9800
17:15980998:TC:T	donor_gain	0.9800
17:15981028:C:A	donor_gain	0.9800
17:15987365:CAGC:C	acceptor_gain	0.9800

AlphaMissense

890 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:15981076:A:C	F90L	0.994
17:15981076:A:T	F90L	0.994
17:15981078:A:G	F90L	0.994
17:15978155:A:C	H105Q	0.984
17:15978155:A:T	H105Q	0.984
17:15978158:C:A	K104N	0.984
17:15978158:C:G	K104N	0.984
17:15978147:G:T	A108E	0.982
17:15981070:G:C	F92L	0.979
17:15981070:G:T	F92L	0.979
17:15981072:A:G	F92L	0.979
17:15978157:G:C	H105D	0.977
17:15987321:A:T	V49D	0.975
17:15978162:C:G	C103S	0.974
17:15978163:A:T	C103S	0.974
17:15981087:A:G	C87R	0.974
17:15978163:A:G	C103R	0.970
17:15978162:C:T	C103Y	0.969
17:15987324:A:G	L48P	0.966
17:15981078:A:T	F90I	0.965
17:15981091:A:C	C85W	0.964
17:15987333:G:T	A45D	0.963
17:15978159:T:A	K104M	0.962
17:15981086:C:T	C87Y	0.961
17:15987334:C:G	A45P	0.960
17:15987271:A:C	Y66D	0.958
17:15978161:G:C	C103W	0.957
17:15981085:A:C	C87W	0.957
17:15978150:A:G	L107S	0.956
17:15981077:A:G	F90S	0.956

dbSNP variants (sampled 300 via entrez): RS1000040309 (17:15977575 G>A,T), RS1000090536 (17:15977463 G>T), RS1000202409 (17:15996307 A>C), RS1000292514 (17:15983457 C>T), RS1000762011 (17:15992088 G>A,C), RS1000801482 (17:15994812 T>C), RS1000848241 (17:15995624 G>A,C), RS1000897881 (17:15982237 T>C), RS1000944190 (17:15989072 T>C), RS1000954043 (17:15989326 T>C), RS1000967598 (17:16000758 C>T), RS1001040737 (17:15976287 A>C), RS1001119722 (17:15982319 C>T), RS1001234266 (17:15982619 G>GTTA), RS1001278497 (17:15989257 G>T)

Disease associations

OMIM: gene MIM:614535 | disease phenotypes: MIM:619834, MIM:619831

GenCC curated gene-disease

Disease	Classification	Inheritance
ovarian dysgenesis 10	Strong	Autosomal recessive
male infertility with azoospermia or oligozoospermia due to single gene mutation	Strong	Autosomal recessive
colorectal adenoma	Limited	Unknown

Mondo (5): ovarian dysgenesis 10 (MONDO:0030736), spermatogenic failure 71 (MONDO:0030787), infertility disorder (MONDO:0005047), colorectal adenoma (MONDO:0005484), (MONDO:0018393)

Orphanet (0):

HPO phenotypes

39 total (30 of 39 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000027	Azoospermia
HP:0000062	Ambiguous genitalia
HP:0000118	Phenotypic abnormality
HP:0000133	Gonadal dysgenesis
HP:0000144	Decreased fertility
HP:0000252	Microcephaly
HP:0000365	Hearing impairment
HP:0000786	Primary amenorrhea
HP:0000823	Delayed puberty
HP:0000837	Increased circulating gonadotropin level
HP:0000869	Secondary amenorrhea
HP:0000938	Osteopenia
HP:0001166	Arachnodactyly
HP:0001251	Ataxia
HP:0001939	Abnormality of metabolism/homeostasis
HP:0002206	Pulmonary fibrosis
HP:0002225	Sparse pubic hair
HP:0002750	Delayed skeletal maturation
HP:0003251	Male infertility
HP:0003621	Juvenile onset
HP:0004322	Short stature
HP:0004349	Reduced bone mineral density
HP:0005625	Osteoporosis of vertebrae
HP:0008209	Premature ovarian insufficiency
HP:0008214	Decreased serum estradiol
HP:0008232	Elevated circulating follicle stimulating hormone level
HP:0008669	Abnormal spermatogenesis
HP:0008684	Aplasia/hypoplasia of the uterus
HP:0008724	Hypoplasia of the ovary

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002587_29	Blood pressure (smoking interaction)	3.000000e-07

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0006335	systolic blood pressure
EFO:0006526	pack-years measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D007246	Infertility	C12.100.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression	2
Valproic Acid	affects expression, decreases methylation	2
bisphenol A	decreases methylation	1
2,5,2’,5’-tetrachlorobiphenyl	increases expression	1
beta-lapachone	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluoro-n-nonanoic acid	increases expression	1
Temozolomide	increases expression	1
Benzo(a)pyrene	increases methylation	1
Demecolcine	increases expression	1
Formaldehyde	increases expression	1
Rotenone	increases expression	1
Smoke	decreases expression	1
Tretinoin	decreases expression	1
Urethane	decreases expression	1
Copper Sulfate	decreases expression	1

Clinical trials (associated diseases)

243 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01767870	PHASE4	UNKNOWN	Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia
NCT07167342	PHASE4	RECRUITING	The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma
NCT01388907	PHASE4	COMPLETED	Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery
NCT01430650	PHASE4	COMPLETED	Endometrial Priming for Embryo Transfer
NCT02607319	PHASE4	COMPLETED	Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure
NCT03169166	PHASE4	COMPLETED	The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies
NCT03177122	PHASE4	UNKNOWN	Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology
NCT03477929	PHASE4	UNKNOWN	Cetrorelix and Ganirelix Flexible Protocol for (IVF)
NCT03619707	PHASE4	COMPLETED	Oral Versus Vaginal Progesterone in the Luteal Support in Cryo-warmed Embryo Transfer Cycles
NCT03846544	PHASE4	COMPLETED	Double Pick up in Poor Prognosis Women
NCT05725512	PHASE4	RECRUITING	Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages
NCT06195163	PHASE4	NOT_YET_RECRUITING	TRAP Study: Testosterone for Androgen Receptor Polymorphism
NCT06763926	PHASE4	NOT_YET_RECRUITING	Intranasal Nafarelin For Triggering Oocyte Maturation
NCT00141193	PHASE3	COMPLETED	Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)
NCT00282386	PHASE3	COMPLETED	A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)
NCT01437826	PHASE3	TERMINATED	Antioxidant Supplement and Reduction of Metachronous Adenomas of the Large Bowel: a Double Blind Randomized Trial
NCT07505056	PHASE3	NOT_YET_RECRUITING	Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas
NCT00749853	PHASE3	SUSPENDED	Efficacy of Ovarian Stimulation Based on FSHR Genotype Status
NCT03238092	PHASE3	UNKNOWN	Comparison Between Testosterone and Estradiol Over the Homogenization of Follicular Cohort
NCT03803228	PHASE3	COMPLETED	Dual Ovarian Stimulation (DUOSTIM) for Poor Ovarian Responders
NCT00582660	PHASE2	COMPLETED	Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib
NCT02134925	PHASE2	ACTIVE_NOT_RECRUITING	Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps
NCT02965703	PHASE2	ACTIVE_NOT_RECRUITING	Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma
NCT03796884	PHASE2	ACTIVE_NOT_RECRUITING	Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer
NCT05402124	PHASE2	UNKNOWN	The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study
NCT06205862	PHASE2	RECRUITING	Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Reducing Recurrence of Colorectal Adenoma (CRA)
NCT06612281	PHASE2	RECRUITING	Evaluation of Gixam’s Performance in a FIT Negative Population
NCT06722950	PHASE2	NOT_YET_RECRUITING	Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy
NCT04701034	PHASE2	COMPLETED	Intravenous Immunoglobulin and Prednisolone for RPL After ART.
NCT04850261	PHASE2	WITHDRAWN	Injection Free IVF
NCT06997900	PHASE2	RECRUITING	Menopur And Rekovelle Combination Study Version 2.0
NCT00298545	PHASE1	COMPLETED	Effect of Vitamin D and Calcium on Genes in the Colon
NCT04952129	PHASE1	COMPLETED	Optimal Selenium for Bowel Polyps (OSCAR)
NCT07095517	PHASE1	RECRUITING	Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
NCT02143505	PHASE2/PHASE3	UNKNOWN	Study of Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence
NCT02226185	PHASE2/PHASE3	COMPLETED	Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence
NCT03281096	PHASE2/PHASE3	COMPLETED	A Research of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer
NCT03333265	PHASE2/PHASE3	COMPLETED	Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride
NCT04216251	PHASE1/PHASE2	COMPLETED	PRevention Using EPA Against coloREctal Cancer
NCT00339950	Not specified	COMPLETED	Colorectal Neoplasia Screening w Colonoscopy in Asymptomatic Women at Regional Navy/Army Medical Ctrs: The CONCeRN Trial